Advertisement
Journal Home
Search for

Volume 121, Issue 12, Pages 1058-1064 (December 2008)


View previous. 12 of 34 View next.

Immunity from Smallpox Vaccine Persists for Decades: A Longitudinal Study

Dennis D. Taub, PhDa, William B. Ershler, MDa, Mark Janowski, MDa, Andrew Artz, MDa, Michael L. Keya, Julie McKelveya, Denis Muller, MSa, Bernard Moss, MD, PhDb, Luigi Ferrucci, MD, PhDa, Patricia L. Duffeya, Dan L. Longo, MDaCorresponding Author Informationemail address

Abstract 

Purpose

The threat of smallpox resulting from bioterrorist action has prompted a reassessment of the level of immunity in current populations.

Methods

We have examined the magnitude and duration of antiviral antibody immunity conferred by smallpox vaccination in 246 participants of the Baltimore Longitudinal Study of Aging. Of this population, 209 subjects were vaccinated one or more times 13 to 88 years before this evaluation, and stored serum samples were available at various intervals after vaccination. An additional 8 subjects who had documented childhood smallpox infection and 29 subjects with no history of infection or vaccination were included. We quantified the total vaccinia IgG and neutralizing antibody titers in each of these subgroups of participants over time.

Results

Vaccinated participants maintained antivaccinia IgG and neutralizing antibody titers above 3 natural logs essentially indefinitely. The absolute titer of antivaccinia antibody was only slightly higher after multiple vaccinations. In 97% of the participants, no decrease in vaccinia-specific antibody titers was noted with age over a follow-up period of up to 88 years. Moreover, Baltimore Longitudinal Study of Aging participants who survived active smallpox infections in their youth retained antivaccinia antibody titers that were similar to the levels detected in vaccinated subjects.

Conclusion

These data suggest that multiple or recent vaccinations are not essential to maintain vaccinia-specific antibody responses in human subjects. Scarce vaccine supplies should be applied first to individuals who have not previously been vaccinated.

a Laboratory of Immunology and the Clinical Research Branch, National Institute on Aging–Intramural Research Program, National Institutes of Health, Baltimore, Md

b Laboratory of Viral Diseases, National Institute of Allergy and Infectious Disease–Intramural Research Program, National Institutes of Health, Bethesda, Md

Corresponding Author InformationRequests for reprints should be addressed to Dan L. Longo, MD, Intramural Research Program, National Institute on Aging, National Institutes of Health, 5600 Nathan Shock Drive, Baltimore, MD 21224-6825

 Funding: This research was supported by the Intramural Research Program of the National Institute on Aging, National Institutes of Health.

 Conflict of interest: None of the authors have any conflicts of interest associated with the work presented in this manuscript.

 Authorship: All authors had access to the data and played a role in writing this manuscript.

PII: S0002-9343(08)00840-1

doi:10.1016/j.amjmed.2008.08.019


View previous. 12 of 34 View next.

Advertisement